GMDA - Earnings announcements

BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 and provide an update on the company on Wednesday, March 27, 2024. Following the release, management will host a conference call and live webcast at 8:30 AM Eastern Time to discuss the financial results and provide a business update. Conference Call Dial-In & Webcast Information: Date/Time:Wednesday, March 27, 2024 at 8:30 AM Eastern TimeDomestic:1-877-425-9470International:1-201-389-0878Conference ID:13744446Call

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the third quarter ended September 30, 2023 and provide an update on the company on Tuesday, November 14, 2023. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide business updates and answer questions. Conference Call Dial-In & Webcast Information:  Date/Time:Tuesday, November 14, 2023 at 8:30 AM Eastern Time Domestic:1-877-425-9470 International:1-201-389-0878 Conference ID:13741

Conference Call and Webcast Scheduled for Monday, August 14th at 8:30 am Eastern Time Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the second quarter ended June 30, 2023 on Monday, August 14, 2023. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates and answer questions. To access the conference call by phone, please register here and be advised to do so at least 10 minutes prior to joining. A live webcast of the conference call can be accessed b

Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to review its first quarter 2023 financial results and provide an update on the company. To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call. A live webcast of the conference call can be accessed in the "Investors & Media" section of the Gamida Cell website at www.gamida-cell.com. A replay of the webcast will be available approximately two hours after the event, for approximately 30 days. Abo

Omisirge is approved by the FDA as a new donor source for allogeneic stem cell transplant Global, randomized Phase 3 clinical trial showed faster neutrophil recovery and reduced bacterial and fungal infections as compared to standard cord blood Omisirge may increase access to stem cell transplant, including among patients from diverse backgrounds Conference call April 18 at 8 am ET Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved Gamida Cell's allogeneic cell therapy, Omisirge® (omidubicel-onlv), for use in adult and pediatric patients 12 years and ol

Company reports on productive interactions with FDA and preparations for launch of omidubicel, if approved, in advance of May 1 PDUFA date Company outlines strategic restructuring, plans to prioritize omidubicel launch and reduce operating expenses to extend cash runway Company to explore strategic options to support a broader launch of omidubicel, including potential US and global partnerships with pharmaceutical companies Company intends to continue GDA-201 Phase 1 study, discontinue development of natural killer (NK) cell preclinical candidates and consolidate its operations in Israel in Kiryat Gat Company to host conference call at 8:00 am ET today Gamida Cell Ltd. (NASDAQ:GMDA), a

Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, March 27, 2023, at 8:00 a.m. ET to review its fourth quarter and full year 2022 financial results and provide an update on the company. To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call. A live webcast of the conference call can be accessed in the "Investors & Media" section of the Gamida Cell website at www.gamida-cell.com. A replay of the webcast will be available approximately two hours after the event, for approximatel

Gamida Cell Ltd. (NASDAQ:GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio webcast on Monday, November 14, 2022, at 8:00 AM EST to review its third quarter 2022 financial results and provide an update on the company. To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call. A live webcast of the conference call can be accessed in the "Investors & Media" section of Gamida Cell's website at www.gamida-cell.com. A replay of the webcast will be available approxima

- Received FDA acceptance of BLA for omidubicel with Priority Review; PDUFA target action date set for January 30, 2023 - - Dosed first patient in company-sponsored Phase 1/2 study of cryopreserved formulation of GDA-201 for the treatment of follicular and diffuse large B-cell lymphomas - - Finished second quarter of 2022 with $55.1 million in cash; sufficient funding for the company's operations into mid-2023, excluding the cost of commercializing omidubicel - - Company to host conference call at 8:00 a.m. ET today - Gamida Cell Ltd. (NASDAQ:GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, to

Gamida Cell Ltd. (NASDAQ:GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio webcast on Monday, August 15, 2022, at 8:00 a.m. ET to review its second quarter 2022 financial results and provide an update on the company. To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call. A live webcast of the conference call can be accessed in the "Investors & Media" section of Gamida Cell's website at www.gamida-cell.com. A replay of the webcast will be available

- If approved, omidubicel will be the first allogeneic advanced stem cell therapy donor source for patients with blood cancers in need of a stem cell transplant - - PDUFA target action date is January 30, 2023 - - Company to host conference call on BLA acceptance and commercial opportunity today at 8:00 a.m. ET - Gamida Cell Ltd. (NASDAQ:GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers i

- On track for full BLA submission of omidubicel in the second quarter of 2022 - - Planning to open sites for enrollment in second quarter of 2022 for Phase 1/2 study of GDA-201 in patients with follicular and diffuse large B-cell lymphomas - - Presented new preclinical data supporting potential of NAM-enabled, genetically modified NK pipeline cell therapy candidates GDA-301 and GDA-601 - - Finished first quarter of 2022 with approximately $70 million in cash; sufficient cash to fund the company's operations into mid-2023 - - Company to host conference call at 8:00 a.m. ET today - Gamida Cell Ltd. (NASDAQ:GMDA), the leader in the development of NAM-enabled cell therapies for patients w

Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, May 10, 2022, at 8:00 a.m. ET to review its first quarter 2022 financial results and provide an update on the company. The webcast will be available on the "Investors & Media" section of the Gamida Cell website at www.gamida-cell.com. To participate in the live call, please dial 866-930-5560 (domestic) or 409-216-0605 (international) and refer to conference ID number 3344029. A replay of the webcast will be available approximately two hours after the event, for approx

- Initiated rolling BLA submission for omidubicel in the first quarter of 2022 with full BLA submission on track for first half of 2022 - - Finished fourth quarter of 2021 with approximately $96 million in cash; sufficient cash to fund the company's operations into mid-2023 - - Company to host conference call at 8:00 a.m. ET today - Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today provided a business update and reported financial results for the year and quarter ended December 31, 2021. Net loss for 2021 was $89.8 million, compared to a net loss of $61.6 million in 2020. As of December 31, 2021, Gamida Cell h

Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, March 15, 2022, at 8:00 a.m. ET to review its fourth quarter and full year 2021 financial results and provide an update on the company. The webcast will be available on the "Investors & Media" section of the Gamida Cell website at www.gamida-cell.com. To participate in the live call, please dial 866-930-5560 (domestic) or 409-216-0605 (international) and refer to conference ID number 1696742. A replay of the webcast will be available approximately two hours after the

Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Monday, November 15, 2021, at 8:00 a.m. ET to review its third quarter 2021 financial results and provide an update on the company. The webcast will be available on the "Investors & Media" section of the Gamida Cell website at www.gamida-cell.com. To participate in the live call, please dial 866-930-5560 (domestic) or 409-216-0605 (international) and refer to conference ID number 4347485. A replay of the webcast will be available approximately two hours after the event, for ap

Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Wednesday, August 11, 2021, at 8:00 a.m. ET to review its second quarter 2021 financial results and provide an update on the company. Management will discuss the company's progress during the quarter, including advances in the development of omidubicel, which has the potential to be the first approved cell therapy for blood cancer patients in need of an allogeneic bone marrow transplant, following the planned BLA submission in the fourth quarter of 2021. Gamida Cell will also